If you made any changes in Pure these will be visible here soon.

Personal profile


Professor of Cardiology and Senior consultant at The Heart Centre Rigshospitalet, University of Copenhagen.

Reviewer for international scientific journals and foundations. Founder and principal investigator of 3 multicenter trials (POSTCON I, POSTCON II, DANAMI3) and principal investigator in a number of trials.

Research according to Web of Science (10.03.23) has been cited >15.000 times, with a H-index of 49. Total publications are >300, with >130 within the latest 5 years (March 2018 – March 2023). Has published 5 articles in the New England Journal of Medicine, 7 in The Lancet and 5 in JAMA.

2007-2016: Head of Department of Invasive Cardiology, The Heart Center, Rigshospitalet.

Main research areas

  • Myocardial protection in ischemic heart disease with special reference to reperfusion injury
  • Percutaneous assist devices in cardiogenic shock
  • The significance of pressure derived strategies in percutaneous coronary interventions
  • Personalized revascularization in frail patients
  • Coronary plaque characterization and intravascular imaging
  • Multivessel disease in STEMI

Current research

Reperfusion strategies in ST-elevation myocardial infarction.

Criricat care medicine in the early setting of ST-elevation myocardial infarction.

Pressure and flow derived revascularization strategies.

Potential conflicts of interest

Advisory board member for Bayer, Astra zeneca, Eli Lilly.


Dive into the research topics where Thomas Engstrøm is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles


Recent external collaboration on country/territory level. Dive into details by clicking on the dots or